EB-PSMA-617

EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity[1].

O=S(O)(C1=CC(S(=O)(O)=O)=C(N)C2=C1C=CC(/N=N/C3=C(C=C(C4=CC(C)=C(C=C4)NC([C@H](CCCCNC(CCN5C(C(CC5=O)SCC(NC[C@@H]6CC[C@H](CC6)C(N[C@@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC7=CC8=C(C=CC=C8)C=C7)=O)=O)=O)=O)NC(CN9CCN(CCN(CCN(CC9)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)C=C3)C)=C2O)=O

[1]Wang Z, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem. 2018 Sep 19;29(9):3213-3221.